secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2025-02-03T23:59:59+00:00
Accession:  0001689375-25-000002
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada gets UK MHRA nod for Phase 1/2 trial of DMD candidate ENTR-601-44
-------------------------------------------------------------------------

- UK MHRA and REC authorized ELEVATE-44-201, a global Phase 1/2 MAD study of ENTR-601-44 for DMD exon 44 skipping.
- Dosing every 6 weeks across three cohorts (6-18 mg/kg); Part A safety/PK/PD, Part B efficacy.
- Company on track to initiate trial in Q2 2025; regulatory filings also submitted in US and EU.
- Prior Phase 1 single-dose study showed ENTR-601-44 well-tolerated with no serious adverse events.
- If eligible, participants may enter an open-label extension for longer-term safety/efficacy assessment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937525000002/0001689375-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937525000002/trda-20250203.htm
  HTML page:      https://secwatch.observer/filing/0001689375-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer